Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620359 | 1.00 | RET (0.41) | RETHCRTR1HCRTR2ACACBFFAR4 | |
| SCHEMBL23703064 | 1.00 | RET (0.41) | RETHCRTR1HCRTR2ACACBFFAR4 | |
| SCHEMBL23708132 | 0.88 | ACACB (0.38) | HCRTR1HCRTR2ACACBPDE10AGPR6 | |
| SCHEMBL29935823 | 0.88 | ACACB (0.38) | HCRTR1HCRTR2ACACBPDE10AGPR6 | |
| SCHEMBL23708279 | 0.88 | ACACB (0.38) | HCRTR1HCRTR2ACACBPDE10AGPR6 | |
| SCHEMBL23702776 | 0.88 | ACACB (0.38) | HCRTR1HCRTR2ACACBPDE10AGPR6 | |
| SCHEMBL29994814 | 0.86 | EGLN1 (0.46) | RETHCRTR1HCRTR2ACACBFFAR4 | |
| SCHEMBL23708179 | 0.86 | EGLN1 (0.46) | RETHCRTR1HCRTR2ACACBFFAR4 | |
| SCHEMBL26620459 | 0.86 | EGLN1 (0.46) | RETHCRTR1HCRTR2ACACBFFAR4 | |
| SCHEMBL23708261 | 0.84 | HCRTR1 (0.42) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118702672-A | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-115335050-B | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-4096661-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2022-12-07 | — | — | EP | disclosed |
| CN-115335050-A | Compounds and compositions for treating skin conditions | 卡玛瑞制药有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220332697-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332697-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | RDX, HAX1, F12 | RET 2321/4885HCRTR1 894/4885HCRTR2 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.